Capital Fund Management S.A. Acquires New Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Capital Fund Management S.A. acquired a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 13,348 shares of the company's stock, valued at approximately $1,075,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PRCT. Lord Abbett & CO. LLC boosted its stake in PROCEPT BioRobotics by 45.3% during the 3rd quarter. Lord Abbett & CO. LLC now owns 748,555 shares of the company's stock valued at $59,974,000 after purchasing an additional 233,430 shares during the last quarter. Perpetual Ltd purchased a new stake in shares of PROCEPT BioRobotics during the fourth quarter worth $66,972,000. Oak Ridge Investments LLC boosted its stake in PROCEPT BioRobotics by 24.0% in the 4th quarter. Oak Ridge Investments LLC now owns 30,059 shares of the company's stock worth $2,420,000 after purchasing an additional 5,817 shares during the period. SG Americas Securities LLC boosted its position in shares of PROCEPT BioRobotics by 295.8% in the fourth quarter. SG Americas Securities LLC now owns 6,598 shares of the company's stock valued at $531,000 after acquiring an additional 4,931 shares during the period. Finally, Chicago Capital LLC boosted its stake in PROCEPT BioRobotics by 44.5% during the fourth quarter. Chicago Capital LLC now owns 379,582 shares of the company's stock valued at $30,564,000 after buying an additional 116,931 shares during the period. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the sale, the chief executive officer now owns 173,070 shares in the company, valued at $9,875,374.20. The trade was a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin Waters sold 733 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now directly owns 107,991 shares in the company, valued at approximately $6,161,966.46. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,455 shares of company stock worth $368,322 over the last three months. 17.40% of the stock is currently owned by corporate insiders.

PROCEPT BioRobotics Trading Up 0.1 %

Shares of NASDAQ PRCT traded up $0.03 during trading hours on Monday, reaching $53.06. The stock had a trading volume of 185,685 shares, compared to its average volume of 780,038. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. The business's fifty day moving average price is $59.16 and its two-hundred day moving average price is $74.66. The firm has a market cap of $2.91 billion, a price-to-earnings ratio of -27.22 and a beta of 1.09. PROCEPT BioRobotics Co. has a 52-week low of $47.04 and a 52-week high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The business had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. Analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Morgan Stanley reduced their price objective on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Truist Financial dropped their price objective on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 11th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $91.43.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).